Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Oct 16;16(1):173.
doi: 10.1186/s12916-018-1168-6.

Registration of published randomized trials: a systematic review and meta-analysis

Affiliations
Meta-Analysis

Registration of published randomized trials: a systematic review and meta-analysis

Ludovic Trinquart et al. BMC Med. .

Abstract

Background: Prospective trial registration is a powerful tool to prevent reporting bias. We aimed to determine the extent to which published randomized controlled trials (RCTs) were registered and registered prospectively.

Methods: We searched MEDLINE and EMBASE from January 2005 to October 2017; we also screened all articles cited by or citing included and excluded studies, and the reference lists of related reviews. We included studies that examined published RCTs and evaluated their registration status, regardless of medical specialty or language. We excluded studies that assessed RCT registration status only through mention of registration in the published RCT, without searching registries or contacting the trial investigators. Two independent reviewers blinded to the other's work performed the selection. Following PRISMA guidelines, two investigators independently extracted data, with discrepancies resolved by consensus. We calculated pooled proportions and 95% confidence intervals using random-effects models.

Results: We analyzed 40 studies examining 8773 RCTs across a wide range of clinical specialties. The pooled proportion of registered RCTs was 53% (95% confidence interval 44% to 58%), with considerable between-study heterogeneity. A subset of 24 studies reported data on prospective registration across 5529 RCTs. The pooled proportion of prospectively registered RCTs was 20% (95% confidence interval 15% to 25%). Subgroup analyses showed that registration was higher for industry-supported and larger RCTs. A meta-regression analysis across 19 studies (5144 RCTs) showed that the proportion of registered trials significantly increased over time, with a mean proportion increase of 27%, from 25 to 52%, between 2005 and 2015.

Conclusions: The prevalence of trial registration has increased over time, but only one in five published RCTs is prospectively registered, undermining the validity and integrity of biomedical research.

Keywords: Randomized controlled trials; Registration; Reporting bias.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flow diagram of study selection
Fig. 2
Fig. 2
Combined estimates of the prevalence of trial registration
Fig. 3
Fig. 3
Combined estimates of the prevalence of prospective trial registration
Fig. 4
Fig. 4
Meta-regression analysis of the prevalence of trial registration in relation to publication year. Each circle represents one study, and the size of each circle represents the weight given to the study in meta-regression. Separate meta-regression models were fitted in 7 studies that reported trial registration data by publication year. The black dashed line corresponds to an overall meta-regression model across these 7 studies with 11 studies that examined RCTs published in a single year. It showed that the proportion of registered trials increased over time, from 23% in 2005 to 52% in 2015 (29% increase, p = 0.03)

References

    1. Zarin DA, Tse T. Medicine. Moving toward transparency of clinical trials. Science. 2008;319(5868):1340–1342. doi: 10.1126/science.1153632. - DOI - PMC - PubMed
    1. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med. 2004;351(12):1250–1251. doi: 10.1056/NEJMe048225. - DOI - PubMed
    1. Chan AW, Song F, Vickers A, Jefferson T, Dickersin K, Gotzsche PC, Krumholz HM, Ghersi D, van der Worp HB. Increasing value and reducing waste: addressing inaccessible research. Lancet. 2014;383(9913):257–266. doi: 10.1016/S0140-6736(13)62296-5. - DOI - PMC - PubMed
    1. Topol EJ. Failing the public health--rofecoxib, Merck, and the FDA. N Engl J Med. 2004;351(17):1707–1709. doi: 10.1056/NEJMp048286. - DOI - PubMed
    1. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364(9450):2021–2029. doi: 10.1016/S0140-6736(04)17514-4. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources